*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My team entered
MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26.
Mirum Pharmaceuticals
MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million.
MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments.
This is a buy and throw away the key type of investment. My teams holding! Will you?
OUR ENTRY: $15.70
FIRST TAKE PROFIT: $26
If you want to see more, please like and follow us @SimplyShowMeTheMoney
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My team entered
Mirum Pharmaceuticals
This is a buy and throw away the key type of investment. My teams holding! Will you?
OUR ENTRY: $15.70
FIRST TAKE PROFIT: $26
If you want to see more, please like and follow us @SimplyShowMeTheMoney
פרסומים קשורים
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
פרסומים קשורים
כתב ויתור
המידע והפרסומים אינם מיועדים להיות, ואינם מהווים, ייעוץ או המלצה פיננסית, השקעתית, מסחרית או מכל סוג אחר המסופקת או מאושרת על ידי TradingView. קרא עוד ב־תנאי השימוש.
